Some Quick Facts About Akero Therapeutics (AKRO)

Small-cap health care company Akero Therapeutics has moved 2.3% this morning, reaching $45.36 per share. In contrast, the average analyst target price for the stock is $59.14.

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The company is based in the United States.

Make Sure to Consider the Following Before Buying Akero Therapeutics:

  • Akero Therapeutics has moved 442.1% over the last year.

  • AKRO has a forward P/E ratio of -13.7 based on its EPS guidance of -3.31.

  • Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 0.3%.

  • The company has a price to earnings growth (PEG) ratio of 1.14.

  • Its Price to Book (P/B) ratio is 6.96

Akero Therapeutics Has Negative Cash Flows

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-12-31 -92,517 nan -92,517 -16.11
2021-12-31 -79,681 nan -79,681 -12.3
2020-12-31 -70,804 -148 -70,952 -99.15
2019-12-31 -35,627 nan -35,627 n/a

Averaging $-69.69 Million over the last 4 years, Akero Therapeutics has consistently negative free cash flows. Their compounded average growth rate over this period is -26.9%, and their coefficient of variability is 35.0%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.